SEER wins patent challenge from Bruker subsidiaries
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
March 30, 2026 7:00 AM EDTREDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the 360 Patent). The inter partes review was filed by PreOmics GmbH and Biognosys AG, each a subsidiary of Bruker Corporation, challenging 11 of 29 claims of the 360 Patent.
The 360 Patent covers methods for analyzing biological samples using engineered nano- and microparticles that... More
